The $400m (€278m) deal, announced in December , adds Orchid’s US Food and Drug Administration (FDA) approved injectables facility in Chennai, India to Hospira’s global manufacturing network.
CEO Christopher Begley said: "Orchid's capabilities provide a platform for future commercial growth, and we look forward to welcoming our new employees, whose talents and skill sets will contribute to Hospira's success."
The deal will also see Orchid supply Hospira with active pharmaceutical ingredients (APIs) under a long-term agreement.